In this review, we report the biological basis and prevalence of KRAS mutations in lung cancer, the molecular techniques for identification of such mutations, the overview of actual therapeutic strategies, the primary and secondary resistance to targeted KRAS agents, and the perspective of KRAS inhibition. The gene discussed is KRAS; the disease is lung carcinoma.